Fibrocell Science (FCSC) Stock Gains 57.30%: What’s Next?

 

Shares of Fibrocell Science Inc (FCSC) stock are up more than 57% Monday following an announcement from the company that it will be collaborating with Castle Creek Pharmaceuticals to develop and commercialize FCX-007 gene therapy.

FCSC stock jumped as high as $3.24, which is 82% higher than Friday’s closing price of $1.78. The average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives FCSC stock a score of 86 out of a possible 100.

That score is chiefly influenced by a fundamental score of 90. In addition to the average rating from Wall Street analysts, FCSC stock has a mean target price of $16.00. This means analysts expect the stock to rise 471.43% over the next 12 months. FCSC’s score also includes a long-term technical score of 87. The short-term technical score for FCSC is 79.

Click Here to get the full Stock Score Report on Fibrocell Science Inc (FCSC).

What’s Happening with FCSC Stock Today

Fibrocell Science Inc (FCSC) stock is higher by 57.26% while the S&P 500 is down -0.15% as of 10:36 AM on Monday, Apr 15. FCSC has risen $1.02 from the previous closing price of $1.78 on volume of 20,622,521 shares. Over the past year the S&P 500 is higher by 8.41% while FCSC is down -12.50%. FCSC lost -$1.45 per share in the over the last 12 months.

Symbols: FCSC

You May Also Like